Mefloquine is a once-weekly antimalarial, which makes it the practical choice for long trips where a daily tablet is hard to sustain. It needs a careful screen for psychiatric and seizure history, and a trial period before departure so any side effects surface at home rather than abroad.

The condition it treats

Malaria is a mosquito-borne parasitic disease that kills travellers every year, with falciparum malaria able to turn fatal within days of first fever. Prevention stacks bite avoidance with chemoprophylaxis matched to the destination's resistance patterns.

How the service runs on Scripter

Patients book online, complete the pre-consultation questionnaire, and the guided pathway walks the practitioner through the malaria prevention consultation with the screening and counselling steps built in. The supply decision, the record and any GP notification are produced in the same flow, documented against the exact protocol version in force.

Training and eligibility requirements.

Who can deliver this service, and who it can be delivered to. The governing PGD document defines the definitive inclusion, exclusion and supply criteria; the Scripter consultation pathway enforces them, and every consultation is documented against the protocol version it ran under.

Practitioner training

✓Registered healthcare professional from a profession authorised to supply under PGDs (Schedule 16, Part 4 of the Human Medicines Regulations 2012), such as a pharmacist, nurse, paramedic or physiotherapist, with current registration with their professional regulator

✓Practising from premises suitable for the service, such as registered pharmacy premises or a registered clinic

✓Assessed clinical competency for this service, declared and reviewed as part of PGD authorisation

✓Sign-off against the current version of this PGD in Scripter before first supply; sign-offs expire automatically when the protocol is updated, and the platform notifies everyone affected

✓In-date basic life support and safeguarding training

✓Indemnity arrangements covering the service

Patient eligibility

✓Travellers to destinations where mefloquine is a recommended option under current national guidance

✓Psychiatric history, epilepsy, cardiac conduction problems and certain interactions screen the patient out per the governing PGD

✓Started two to three weeks before entry so tolerability is known before travel, continued for four weeks after leaving

✓Bite prevention and fever-warning counselling completed

Mefloquine PGD questions

Who is mefloquine right for?+

Travellers on long trips to destinations where it is recommended, with no history of depression, anxiety, psychosis or seizures. The weekly dose is its advantage; the screening is not optional.

Why start so early?+

Beginning two to three weeks before departure lets the traveller find out at home whether they tolerate it, with time to switch regimen if not.

How long after returning must it continue?+

Four weeks. The post-travel doses clear parasites still incubating in the liver.

More travel health PGDs.

Related protocols in the same category, all delivered through the same platform.

Run a malaria prevention service without the paperwork.

See the consultation pathway, the sign-off tracking and the record it produces in a free 30-minute demo.

Book a demo Contact us

Built for pharmacists, by pharmacists.